. The success of therapies that disrupt PD-L1-mediated tumour tolerance has highlighted the need to understand the molecular regulation of PD-L1 expression 1 . Here we identify the uncharacterized protein CMTM6 as a critical regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen. CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression. CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degradation. Using a quantitative approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1. Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I. CMTM6 depletion, via the reduction of PD-L1, significantly alleviates the suppression of tumour-specific T cell activity in vitro and in vivo. These findings provide insights into the biology of PD-L1 regulation, identify a previously unrecognized master regulator of this critical immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumour cells.
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The interaction between PD-1 on T cells and PD-L1 on tumour cells inhibits activation, expansion and effector functions of antigen-specific CD8 + T cells and helps cancer cells evade immune destruction 1, 2 . PD-L1 expression may be induced in response to inflammatory cytokines such as interferon-γ (IFNγ ) secreted by immune cells within the tumour microenvironment or can be driven by tumour-cell-intrinsic mechanisms, including amplification of the PD-L1 (also known as CD274) locus 3 and structural variation of the 3′ region of the PD-L1 gene 4 . To identify new regulators of both constitutive and induced cell surface PD-L1 expression, we performed a whole-genome CRISPRCas9 deletion library screen 5 in the pancreatic cancer cell line BxPC-3, which displays endogenous PD-L1 that can be further induced by IFNγ (Fig. 1a, Extended Data Fig. 1 ). Following stimulation with IFNγ , our screen identified the key components of the IFNγ pathway as well as CKLF-like MARVEL transmembrane domain containing protein 6 (CMTM6) (Fig. 1b) . In the absence of IFNγ , CMTM6 was the only identified regulator of PD-L1 expression (Fig. 1c) . Depletion of CMTM6 using specific single-guide RNAs (sgRNAs) or short hairpin RNAs (shRNAs) led to a marked reduction in total cellular levels of PD-L1 (Fig. 1d, Extended Data Fig. 1c, d ). These findings have broad relevance as CMTM6 is a major regulator of PD-L1 expression in cell lines representative of melanoma, breast and lung cancer ( and IFNγ -induced PD-L1 expression without compromising antigen presentation by reducing cell surface MHC class I levels (Extended Data Fig. 4 ). Exogenous expression of CMTM6 in CMTM6-knockout cells regulates PD-L1 in a dose-dependent manner and restores both total and cell surface PD-L1 levels (Fig. 1f, Extended Data Fig. 5a ). In myeloid lineage cells, CMTM6 depletion specifically downregulates cell surface expression of PD-L1 but not PD-L2 (Extended Data Fig. 6a, b) . Interestingly, CMTM6 levels are not influenced by IFNγ stimulation (Extended Data Figs 1c, 4b, 5b) and, in contrast to other recently described regulators of PD-L1 expression 1, 2 , CMTM6 does not function as a transcriptional regulator of PD-L1 either in the presence or absence of IFNγ (Fig. 1g) .
CMTM6 belongs to a family of proteins, primarily encoded by two distinct gene clusters, on chromosome 16 (CMTM1-4) and chromosome 3 (CMTM6-8) 6 . Although largely uncharacterized, CMTM family members contain a MARVEL domain comprising at least three transmembrane helices 7 . Interestingly, MARVEL domain proteins have been implicated in regulating trafficking of transmembrane and secretory proteins 7 . To determine whether CMTM6 interacts with PD-L1, we performed reciprocal co-immunoprecipitation experiments using detergent conditions that solubilize the membrane to a variable degree. CMTM6 was readily detected in association with PD-L1; however, this interaction is maintained only under conditions that preserve the integrity of a membrane-associated complex (Fig. 2a, b) . In agreement with this, CMTM6 co-localizes with PD-L1 at the cell surface both in the presence and absence of IFNγ stimulation (Fig. 2c, Extended Data Fig. 5c, d) .
As CMTM6 is an uncharacterized protein localized at the cell surface, we investigated which other proteins associate with CMTM6 under conditions that preserve its membrane-dependent interactions. CMTM6 was immunoprecipitated from digitonin lysates of IFNγ -treated cells and subjected to mass spectrometry analysis. After eliminating proteins identified in control immunoprecipitates, only a small number of high-confidence interacting proteins were identified, of which PD-L1 was one of the top ranked (Extended Data Fig. 6c and Supplementary Table 1) . To gain a comprehensive unbiased overview of plasma membrane proteins with altered expression following CMTM6 depletion, we combined plasma membrane enrichment through selective aminoxy-biotinylation (plasma membrane profiling) 8 with tandem mass tag (TMT)-based quantitative proteomics 9 (Fig. 2d) . Following CRISPR-Cas9-mediated disruption of CMTM6 with two independent sgRNAs (Fig. 1d) , we exploited 10-plex TMT labelling to profile the cell surface proteome of wild-type and CMTM6-depleted MDA-MB-231 breast cancer cells in triplicate. In total, 4,935 proteins were quantified, including 1,424 proteins previously reported to localize to the plasma membrane. Notably, PD-L1 was one of only four proteins reproducibly decreased more than twofold from the plasma membrane (Fig. 2e and  Supplementary Table 2 ). Taken together, the absolute requirement for CMTM6 for PD-L1 cell surface expression and the physical association between CMTM6 and PD-L1, establish CMTM6 as a new regulatory target to specifically vary the cell surface expression of this critical immune checkpoint molecule.
PD-L1 is a type I transmembrane protein with four N-linked glycans that, when modified by Golgi-resident enzymes, become resistant to endoglycosidase H (EndoH) digestion permitting visuali zation of PD-L1 trafficking through the secretory pathway. To exa mine the maturation of newly synthesized PD-L1, IFNγ -stimulated cells were pulse-labelled with 35 S-cysteine/methionine. EndoH-resistant PD-L1 species emerged at a similar rate in control and CMTM6-knockout cells, indicating that loss of CMTM6 does not impair PD-L1 export from the endoplasmic reticulum and trafficking beyond the medial Golgi (Fig. 3a) . Although PD-L1 levels in the early part of Experiments performed twice. b, Interaction of CMTM6 with PD-L1 is detergent-sensitive. Cells were lysed in 1% digitonin (Dig) and adjusted to the indicated detergent concentrations before immunoprecipitation of PD-L1. Experiment performed twice. Tx, Triton X-100. c, PD-L1 and CMTM6
co-localize at the plasma membrane. PD-L1-knockout, CMTM6-knockout and parental MDA-MB-231 Cas9 cells were fixed, immunostained for PD-L1 and CMTM6 and analysed by confocal microscopy. Scale bar, 10 μ m. d, e, Quantitative plasma membrane profiling. d, Experimental workflow. e, Scatterplots display pairwise comparisons between parental MDA-MB-231 Cas9, CMTM6 sgRNA1 and CMTM6 sgRNA2-expressing cells. Experiment performed in triplicate. Q values determined using LIMMA with Benjamini-Hochberg adjustment for multiple testing.
the chase were equivalent in wild-type and CMTM6-knockout cells, accelerated degradation of EndoH-resistant PD-L1 was evident at later time-points (Extended Data Fig. 6d ). Consistent with this, PD-L1 cell surface expression increased in CMTM6-knockout cells for the first 6 h after IFNγ was added (Extended Data Fig. 6e-g ), but beyond this time-point only wild-type cells were able to further augment and sustain PD-L1 expression (Extended Data Fig. 6e, f) . Together, these findings show that CMTM6 is not required for the trafficking of PD-L1 from the endoplasmic reticulum to the cell surface, but may be required for stable expression of PD-L1 at the plasma membrane.
To establish whether CMTM6 regulates PD-L1 at the cell surface, we labelled surface PD-L1 with PD-L1-specific antibodies at 4 °C before transferring cells to 37 °C to allow PD-L1 internalization and either degradation or recycling back to the plasma membrane ( Fig. 3b-e) . When evaluated either by flow cytometry (Fig. 3b, c) or by immunoprecipitation (Fig. 3d, e) , degradation of antibody-labelled PD-L1 from the cell surface was markedly accelerated in the absence of CMTM6, for CMTM6 (left) or PD-L1 (right) plus markers of the ER (calnexin (CANX)), Golgi (GM130 and TGN46), early endosome (EEA1), late endosome/lysosome (LAMP1) or recycling endosome (RAB11 and transferrin receptor (TFRC)). Scale bar, 10 μ m. g, h, PD-L1 recycling is impaired in the absence of CMTM6. g, IFNγ -treated WM-852 cells were labelled with an unconjugated PD-L1-specific antibody before incubation at 37 °C ± primaquine (described in Extended Data Fig. 8a ). Remaining antibody-labelled surface PD-L1 was detected with an AF647-conjugated anti-mouse antibody and analysed by flow cytometry. h, PD-L1 recycling in IFNγ -treated WM-852 cells (assay described in Extended Data Fig. 8c) . Graph shows the proportion of internalized antibody-labelled PD-L1 recycled at each time-point. g, h, Mean and s.e.m. from 3 experiments.
Letter reSeArCH 1 0 4 | N A t U r e | V O L 5 4 9 | 7 s e p t e m b e r 2 0 1 7 whereas cell surface MHC class I labelled under the same conditions remained stable (Extended Data Fig. 7a ). To understand how CMTM6 may function to stabilize cell surface PD-L1, we examined the subcellular localization of CMTM6 using confocal immuno fluorescence microscopy ( Fig. 3f) . In addition to its expression at the plasma membrane, CMTM6 is predominantly identified in recycling endosomes where it co-localizes with TFRC and RAB11, molecules that define the endocytic recycling compartment 10 (Fig. 3f) . Subcellular localization of PD-L1 also identified PD-L1 in recycling endosomes (Fig. 3f, Extended Data Fig. 7b) . Notably, incubation with primaquine, an inhibitor of endocytic recycling 11 , induced rapid loss of PD-L1 from the surface of wild-type cells suggesting that a large proportion of surface PD-L1 is continuously internalized and recycled (Fig. 3g , Extended Data Fig. 8a ). In contrast, primaquine did not substantially increase the PD-L1 internalization rate in CMTM6-knockout cells, implying that the failure to maintain PD-L1 at the plasma membrane in the absence of CMTM6 is primarily due to defective endocytic recycling (Fig. 3g) . In support of this, we found, using established recycling assays 12 , that the majority of internalized PD-L1 in control cells recycled back to the cell surface after 10 to 15 min; however, in the absence of CMTM6, PD-L1 recycling was markedly impaired (Fig. 3h , Extended Data Fig. 8b, c ). These data demonstrate that endocytosed PD-L1 is not effectively recycled in CMTM6-deficient cells and may instead be rerouted for degradation in the lysosome. Consistent with this, incubation with inhibitors of lysosomal acidification stabilizes PD-L1 in CMTM6-deficient cells (Fig. 4a-d, Extended Data Fig. 9a-c) ; however, PD-L1 remains sequestered within the cell and cannot recycle to the cell surface (Fig. 4e, Extended Data Fig. 9d ).
The success of anti-cancer therapies targeting the PD-1-PD-L1 immune checkpoint lies in their ability to potentiate anti-tumour immunity 13 . Clinical data supporting the value of anti-PD-1-PD-L1 blockade is most advanced in melanoma 14 , so we used co-culture experiments with melanoma cells to evaluate the effects of CMTM6 depletion on T cell responses. Co-culture with Jurkat T cells, which respond to PD-1 inhibition 15 , showed that tumours depleted of either CMTM6 or PD-L1 potentiated Jurkat IL-2 secretion to a similar degree (Extended Data Fig. 9e ). To extend these findings using primary cells, we isolated and expanded antigen-specific cytotoxic T lymphocyte clones (CTLs) recognizing distinct HLA-restricted epitopes from the cancer testis-antigen NY-ESO-1 from patients with melanoma 16, 17 . These CTLs were co-cultured with the HLA-A2 NY-ESO-1-positive melanoma line A375 and early-passage HLA-Cw3-positive NY-ESO-1-positive cell lines derived from primary melanoma patient samples 16 . These melanoma lines were incubated with IFNγ before co-culture to induce PD-L1 expression (Extended Data Fig. 9f-h ). Melanoma cells with decreased cell surface expression of PD-L1 following CMTM6-knockout were killed more efficiently by NY-ESO-1 157-165 -and NY-ESO-1 92-100 -specific CTLs, which expressed high levels of PD-1 (Extended Data Fig. 10a-e) . Moreover, co-culture with CMTM6-depleted tumour cells significantly enhanced T lymphocyte activation as indicated by an increased proportion of perforin-and TNFα -producing CD8
+ T cells (Fig. 4f, Extended Data Fig. 10f ), increased IFNγ and IL-2 secretion (Fig. 4g ) and augmented production of proinflammatory chemokines (Extended Data Fig. 10g ). Notably, deleting PD-L1 or adding a saturating concentration of PD-1-blocking antibody to the co-culture enhanced T cell activation to a similar degree as CMTM6 depletion (Fig. 4f, g ).
To examine the effects of CMTM6 on tumour control in vivo we used RNA interference to deplete CMTM6 in B16F10 mouse melanoma expressing the foreign antigen chicken ovalbumin (OVA) to enhance the immunogenicity of the tumours. Survival of mice transplanted with CMTM6-depleted cells was significantly increased compared to control-shRNA-expressing cells (Fig. 4h) . This reflected overall attenuated growth of CMTM6-deficient tumours, despite some inter-and intra-experimental variability in the responses, which may represent the contribution of PD-L1 expressed in the tumour microenvironment (Fig. 4i , Extended Data Fig. 10h-j) . Together our ex vivo human data and in vivo mouse data demonstrate that CMTM6 functions as a key regulator of T-lymphocyte-mediated anti-tumour immunity by modulating cell surface expression of PD-L1.
Harnessing the immune system has emerged as an essential part of therapy in oncology. Key to this success has been the development of drugs that release the constraints of immune checkpoints 1 and insights into the molecular regulation of essential checkpoint molecules therefore offer unique opportunities for innovative therapies. Here, we have shown that CMTM6, a previously uncharacterized protein, is a master regulator of PD-L1 cell surface expression across various cancer types. CMTM6 associates with PD-L1 at the plasma membrane and in recycling endosomes, where it protects PD-L1 from being targeted for lysosomal degradation. CMTM6 shows significant specificity for PD-L1 and does not compromise antigen presentation via MHC class I, suggesting that it could serve as a specific therapeutic target to enhance anti-tumour immunity to an extent that is comparable to anti-PD-1 therapies in clinical use. As existing immune checkpoint therapies are not universally effective and may be limited by toxicities 18 , identifying novel immunotherapies and combination strategies is a major priority 19 . These findings establish CMTM6 and its regulatory pathway as a potential new therapeutic avenue to enhance tumour specific immunity.
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Cell culture. WM-852 cells were obtained from the European Searchable Tumour Line Database (ESTDAB) cell line repository and BxPC-3 cells were a gift from Y. Wang (Barts Cancer Institute, London). HEK 293ET cells, were a gift from F. Randow (MRC-LMB, Cambridge, UK). HCC-827, MDA-MB-231 and A375 were obtained from ATCC. The patient-derived melanoma cell lines LM-MEL-53 and LM-MEL-44 were established and characterized as previously described 16 . Cells were cultured in RPMI-1640 or DMEM (BxPC-3, HEK-293ET and B16F10-OVA) supplemented with 2 mM glutamax, 100 IU ml −1 penicillin, 100 μ g ml −1 streptomycin and 10% heat-inactivated fetal calf serum.
Cell lines were authenticated by STR profiling through the Victorian Centre for Functional Genomics. Most recent authentication, 1 March 2017. Cell lines were regularly tested and verified to be mycoplasma negative by PCR analysis by the Victorian Infectious Diseases References Laboratory (Melbourne, Victoria). CRISPR-Cas9-mediated gene disruption. sgRNA oligonucleotides (SigmaAldrich) were phosphorylated and annealed and cloned into lentiviral expression vectors, pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene 50946, deposited by K. Yusa), or FgH1tUTG (Addgene 70183, a gift from M. Herold) for inducible sgRNA expression. For CRISPR-Cas9-mediated gene disruption, cells were first transduced with the Cas9 expression vector pHRSIN-P SFFV -Cas9-P PGK -Blasticidin, selected with blasticidin, and then subsequently transduced with a lentiviral sgRNA expression vector. For transient sgRNA expression using FgH1tUTG, cells were treated with doxycyline for one week. CMTM6-knockout and PD-L1-knockout clones were isolated by single-cell dilution cloning from polyclonal sgRNA-transduced populations. Knockout clones were identified by flow cytometry analysis for cell surface PD-L1 followed by immunoblot for CMTM6 and PD-L1. Lentiviral production and transduction. Lentivirus was produced by triple transfection of HEK-293ET cells with a lentiviral transfer vector, and the packaging plasmids psPAX2and pMD.G at a 0.5:0.35:0.15 ratio. Transfection was performed using JetPEI reagent as recommended by the manufacturer. The viral supernatant was collected 48 h following transfection, filtered through a 0.45 μ m filter, and added to target cells.
For lentiviral expression of shRNAs, shRNAs targeting CMTM6 or nontargeting control shRNAs were cloned into the pHR-SIREN vector, which co-expresses a GFP selection marker, via BamHI and EcoRI. CRISPR sgRNA Library. A 10-sgRNA-per-gene CRISPR-Cas9 deletion library was designed to target all ~ 20,500 protein-coding human genes. The library contained two distinct classes of negative control gRNAs: non-targeting control sgRNA with no binding sites in the genome and safe-targeting sgRNA targeting genomic locations with no annotated function. Further details are described in Morgens et al.
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. CRISPR screen. BxPC-3 cells were transduced with a lentiviral vector encoding Cas9 and selected with blasticidin. 10 8 cells BxPC-3 Cas9 cells were infected with the pooled lentiviral genome-wide sgRNA library at a multiplicity of infection of 0.3 and selected with 1 μ g ml −1 puromycin for 72 h, commencing 48 h after transduction. Rare PD-L1 low cells were enriched by two rounds of FACS sorting at day 7 and day 15 following transduction with the sgRNA library. For the sorts, cells (at least 10 8 for the first sort) were pre-treated with or without 500 IU ml −1 IFNγ for 48 h, collected with trypsin, stained with APC-conjugated anti-PD-L1 antibody (MIH1, eBioscience) for 15 min on ice and washed with PBS before sorting for mCherry-positive (sgRNA expressing) PD-L1 low cells on a BD Influx cell sorter. Genomic DNA was extracted (Puregene Core Kit A, Qiagen) from both the sorted cells and an unselected pool of mutagenized cells grown for the same amount of time. sgRNA sequences were amplified by two rounds of PCR, with the second round primers containing adaptors for Illumina sequencing. The resulting libraries were sequenced with single-end 50 bp reads on a HiSeq2500. The sequence reads were trimmed to remove the constant portion of the sgRNA sequences with fastx clipper (http://hannonlab.cshl.edu/fastx_toolkit/), then mapped to the reference sgRNA library with bowtie2. After filtering to remove multi-aligning reads, the read counts were computed for each sgRNA. The RSA algorithm was used to rank the genes for which targeting sgRNA were significantly enriched in the sorted populations compared to the control unsorted populations grown in parallel. The P value cut-off for significance was adjusted to account for multiple-testing using the Bonferroni correction. Immunoblotting and immunoprecipitation. For immunoblotting cells were lysed either in 1% Triton X-100 in TBS pH7.6 with Roche complete protease inhibitor for 30 min on ice followed by pelleting of insoluble material by centrifugation, or in 1% SDS in 100 mM Tris-HCl pH 8.0 plus benzonase (Sigma) at room temperature. Lysates were heated to 70 °C in SDS sample buffer with 50 mM DTT for 10 min, separated by SDS-PAGE, and transferred to PVDF membrane (Millipore). Membranes were blocked in 5% milk in TBS + 0.1% Tween-20, probed with the indicated antibodies, and reactive bands visualized using West Pico (Thermo Fisher Scientific).
For co-immunoprecipitation experiments, cells were lysed in 1% digitonin for 30 min on ice. Post-nuclear supernatants were adjusted to 0.5% digitonin or to the detergent concentration indicated in the figures, incubated with primary antibody for 1-4 h, followed by addition of protein A or protein G dynabeads and incubation for a further 2 h at 4 °C. After four washes in 0.2% digitonin, samples were eluted in SDS sample buffer with 50 mM DTT for 10 min at 70 °C, separated by SDS-PAGE and immunoblotted as described.
For immunoprecipitation of cell surface PD-L1, live cells were incubated with anti-PD-L1 antibody (MIH1, 10 μ g ml
) for 60 min on ice. After three washes in ice-cold PBS to remove unbound antibody, cells were resuspended in pre-warmed complete medium (RPMI/10% FCS) and incubated at 37 °C for the indicated times. Cells were placed back on ice, washed once in PBS and lysed in 1% NP-40/TBS pH 7.6 plus Roche complete protease inhibitor. Post-nuclear supernatants were incubated with protein G dynabeads for 3 h at 4 °C to capture antibody-bound PD-L1. After four washes in 0.2% NP-40, samples were eluted in SDS sample buffer with 50 mM DTT for 10 min at 70 °C, separated by SDS-PAGE and immunoblotted as described. Metabolic labelling and pulse-chase. Cells were starved for 20 min in methionine-free, cysteine-free medium, labelled with 35 S-methionine/cysteine (Perkin-Elmer) for 30 min and then chased in medium containing excess cold methionine and cysteine (Sigma-Aldrich) at 37 °C. Samples taken at the indicated time-points were lysed in 1% NP-40/TBS pH 7.6 with Roche complete protease inhibitor and 10 mM iodoacetamide (IAA). Post-nuclear supernatants were precleared with a combination of IgG-sepharose and protein G dynabeads for 1-2 h on a rotator at 4 °C, and then incubated (rotating) with a PD-L1-specific antibody (AF156, R&D systems) for 1 h before adding protein G dynabeads for a further 2 h at 4 °C. After 4 washes in 0.2% lysis buffer, samples were eluted in SDS sample buffer for 10 min at 70 °C. Where indicated, eluates were treated with endoglycosidase H (New England Biolabs) according to the manufacturer's instructions before separation by SDS-PAGE. Gels were fixed, dried at 80 °C for 2 h and processed for autoradiography. Phosphor screens were exposed to the radiolabelled proteins in fixed, dried gels overnight. Screens were scanned using a TYPHOON scanner and bands quantified using ImageJ. Plasma membrane profiling by mass spectrometry. Plasma membrane profiling was performed as previously with minor modifications. MDA-MB-231 cells expressing either Cas9 alone or Cas9 plus one of two sgRNAs targeting CMTM6 were cultured to ~ 80% confluence (3× 14-cm dishes each). Cells were washed in PBS before biotinylation of the cell surface, washing and collection by scraping. Cells were lysed in 1% Triton X-100 in TBS pH 8 with protease inhibitors (Complete EDTA-free, Roche) and incubated at 4 °C for 30 min with end-over-end agitation. Following centrifugation (10,000g for 10 min), supernatants were applied to 50 μ l of High-Capacity streptavidin-agarose resin (Thermo Fisher Scientific) and incubated at 4 °C for 2 h. Samples were applied to 500 μ l fritted micro columns (Snap-Cap, Thermo Fisher Scientifc) and washed using a vacuum manifold with 20 × 400 μ l lysis buffer, 20 × 400 μ l 0.5% SDS in PBS a 10 × 400 μ l 6 M urea in 50 mM TEAB buffer (pH 8). Beads were resuspended in 400 μ l urea wash buffer containing 10 mM TCEP and 10 mM iodoacetamide and incubated for 30 min in the dark at room temperature to effect reduction and alkylation of cysteines. Following 10 × 400 μ l washes with urea wash buffer and 5 × 400 μ l washes with 50 mM TEAB, beads were recovered into LoBind Eppendorf tubes, spun briefly and supernatant removed before resuspending in 50 μ l of 50 mM TEAB containing 0.5 μ g trypsin (Proteomics Grade, Thermo Fisher). Samples were incubated at 37 °C for 8 h in a Thermo mixer C at 1,200 r.p.m. Subsequently samples were recovered from streptavidin beads and the beads washed once with 50 μ l 50 mM TEAB. Samples were dried in a vacuum centrifuge and resuspended in 20 μ l 50 mM TEAB.
Letter reSeArCH TMT labelling. To each tube, 0.2 μ g of a unique TMT label for each sample was added in 8.5 μ l acetonitrile and incubated for 1 h at room temperature. Labels were as follows. Control: 126, 127N, 127C. sgRNA 1: 128N, 128C, 129N. sgRNA 2 129N, 130N, 130C. TMT reactions were quenched by addition of 3 μ l of 200 mM ammonium formate, pooled and dried in a vacuum centrifuge. The sample was resuspended in 800 μ l 0.1% TFA and acidified to ~ pH 2 with formic acids before performing a C18-SPE cleanup using a Sep-Pak cartridge (Waters) attached to a vacuum manifold. C18 Eluate was dried in a vacuum centrifuge and resuspended in 40 μ l 200 mM ammonium formate, pH 10. High pH reversed-phase fractionation. Sample was injected onto an Ultimate 3000 RSLC UHPLC system (Thermo Fisher Scientific) equipped with a 2.1 i.d. × 25 cm, 1.7 μ m particle Kinetix Evo C18 column (Phenomenex). Mobile phase consisted of A: 3% ACN, B: ACN and C: 200 mM ammonium formate pH 10. Isocratic conditions were 90% A/10% C and C was maintained at 10% throughout the gradient elution. Separations were carried out at 45 °C. After loading at 200 μ l min −1 for 5 min and ramping the flow rate to 400 μ l min −1 over 5 min the gradient elution proceed as follows: 0-19% B over 10 min (curve 3), 19-34% B over 14.25 min (curve 4), 34-50% B over 8.75 min (curve 5), followed by a 10 min wash at 90% B. Ultraviolet absorbance was monitored at 280 nm and 15-s fractions were collected into 96-well microplates using the integrated fraction collector. Peptidecontaining fractions were then orthogonally recombined into 12 fractions and dried in a vacuum centrifuge and resuspended in 10 μ l 5% DMSO 0.5% TFA for analysis. LC-MS analysis. All samples were injected onto an Ultimate 3000 RSLC nano UHPLC equipped with a 300 μ m i.d. × 5 mm Acclaim PepMap μ -Precolumn (Thermo Fisher Scientific) and a 75 μ m i.d. × 75 cm 2.1-μ m particle Acclaim PepMap RSLC analytical column. Loading solvent was 0.1% TFA, analytical solvent A: 0.1% FA and B: ACN+ 0.1% FA. All separations were performed at 55 °C. Samples were loaded at 10 μ l min −1 for 5 min in loading solvent before beginning the analytical gradient. For high pH RP fractions a gradient of 3-5.6% B over 4 min, 5.6-32% B over 162 min, followed by a 5 min wash at 80% B, a 5 min wash at 90% B and equilibration at 3% B for 5 min. For immunoprecipitation samples a linear gradient from 3-5.6% B over 8 min and 5.6-32% B over 72 min, followed by a 5 min wash at 80% B and a 5 min wash at 90% B and equilibration at 3% B for 5 min. Search results were further processed and filtered as follows: peptides below a percolator FDR of 0.01% and proteins below the 0.01% protein FDR (calculated from a built-in decoy database search) were rejected. Protein groups were then generated using the strict parsimony principle. Peptides both unique and razor with a co-isolation threshold of 50 and an average s/n threshold of 10 were used for quantification and a normalization of these values on the total peptide amount in each channel was applied. Instances in which a protein was identified but not quantified in all channels were rejected from further analysis. Manual interpretation of the data did not reveal any protein conspicuously absent from any sample set. Processed data were analysed in R using a custom script to apply the moderated t-test LIMMA, including Benjamini-Hochberg correction for multiple hypotheses. Supplementary Table 2 holds all data from the experiment. Co-immunoprecipitation and mass spectrometry. IFNγ -treated MDA-MB-231 cells, and CMTM6-knockout cells as a negative control, were lysed in 1% digitonin with Roche complete protease inhibitor and 10 mM iodacetamide. Post-nuclear supernatants were adjusted to 0.5% digitonin and pre-cleared with protein A dynabeads for 2 h, incubated with rabbit anti-CMTM6 primary antibody (Sigma, HPA026980) for 2 h followed by addition of protein A dynabeads for a further 2 h at 4 °C. Following four washes in 0.2% digitonin, samples were eluted in SDS sample buffer with 50 mM DTT at 70 °C for 10 min. Eluates were run ~ 1 cm into NuPage 4-12% BIS-TRIS polyacrylamide gels (Invitrogen), stained with Coomassie (Simply Stain, Invitrogen) and cut into ~ 1 mm square pieces. Gel pieces were destained overnight in 50% ACN, shrunk in 100% ACN and rehydrated in 50 mM TEAB (pH 8.5), 10mM TCEP, 10 mM Iodoacetamide and incubated at room temperature for 30 min in the dark. Gel pieces were shrunk in ACN, rehydrated in 50mM TEAB and finally shrunk in ACN and dried briefly in a vacuum centrifuge. Gel pieces were incubated in 50 mM TEAB with 10 ng μ l −1 trypsin on ice for 30 min before 50 mM TEAB incubation overnight at 37 °C in 50 mM TEAB. Peptides were recovered by sequential shrink/rehydrate cycles of ACN, 5% FA, ACN and dried in a vacuum centrifuge. Prior to analysis they were resuspended in 10 μ l 5% DMSO 0.5% TFA. Samples were acquired on the same platform as for the plasma membrane profiling experiments. A threshold of 0.01% PSM and 0.01% protein FDR was used as a cut-off for identification. To identify specific interaction partners of CMTM6, the data were filtered to remove proteins also present in control immunoprecipitations from CMTM6-knockout cells (Supplementary Table 1) . Flow cytometry. Cells were washed in PBS and stained for cell surface PD-L1 or MHC class I on ice for 20 min in PBS plus 2% FCS. After washing in PBS samples were analysed on a BD LSR Fortessa and analysed in FlowJo. Endocytosis and recycling assays. Assays were performed using three different WM-852 melanoma CMTM6-knockout clones (shown in Extended Data Fig. 5a ) and parental Cas9-expressing cells. All cells were pre-treated with IFNγ 500 IU ml −1 for 18-24 h before starting the assays. Internalization assay. Cells were collected with TrypLE Express, placed on ice and washed once in RPMI/5% FCS/30 mM HEPES (used for all staining and wash steps). Cell surface PD-L1 was labelled with unconjugated anti-PD-L1 (29E.2A3, Biolegend) for 1 h on ice and washed twice to remove unbound antibody. Cells were resuspended in RPMI medium on ice and a baseline sample removed and kept on ice. Cells were incubated at 37 °C in a water bath, in the presence of 300 μ M primaquine where indicated, and samples were removed at the indicated times and immediately diluted in ice-cold PBS to stop further endocytosis. Cells were washed twice, and remaining surface-bound anti-PD-L1 antibody stained with Alexa Fluor-647-conjugated anti-mouse secondary antibody for 30 min on ice. Samples were washed twice and analysed by flow cytometry. Degradation assay. Cells were labelled as previously described with an APCconjugated PD-L1 specific (29E.2A3) or MHC-class-I-specific antibody (W6/32). After washing as described, cells were replated in complete medium and incubated at 37 °C, in the presence or absence of lysosome inhibitors as indicated in the figure legends. The APC-conjugated antibody continues to fluoresce after internalization and the degradation of cell surface-labelled PD-L1-MHC class I is reflected by loss of fluorescence intensity over time. At the indicated times, cells were collected by brief incubation with TrypLE Express, washed twice and fixed for 10 min in 4% PFA before analysis by flow cytometry. Recycling assay 1. Cell surface PD-L1 was labelled with unconjugated anti-PD-L1 (29E.2A3, Biolegend) for 1 h on ice as described. Cells were incubated at 37 °C for 30 min to allow endocytosis of antibody-labelled PD-L1. After washing, remaining surface bound antibody was stripped by two rounds of resuspension in low pH buffer (0.5 M NaCl, 0.5% acetic acid, pH 2.5-2.8) for 2 min on ice, followed by neutralisation with RPMI/5% FCS/30 mM HEPES. A baseline sample was kept on ice and cells were returned to 37 °C to allow PD-L1 recycling. Samples taken at the indicated times were stained with Alexa Fluor-647-conjugated anti-mouse secondary antibody for 30 min on ice and analysed by flow cytometry. Recycling assay 2. Cell surface PD-L1 was stained with an AF488-conjugated anti-PD-L1 antibody (Abcam) on ice for 1 h then washed twice. A pre-endocytosis control sample was kept on ice and remaining cells were incubated at 37 °C for 30 min to allow endocytosis of antibody-labelled PD-L1. The remaining surface-bound AF488-conjugated anti-PD-L1 antibody was quenched by incubation with an anti-AF488 antibody (Invitrogen) for 1 h on ice. Cells were washed twice and returned to 37 °C to allow PD-L1 recycling. Samples taken at the indicated times were returned to ice, split and incubated with or without anti-AF488 antibody to quench anti-PD-L1-AF488 recycled to the cell surface. Samples were analysed by flow cytometry. After normalization for incomplete quenching by subtracting the quenchable AF488 signal present at baseline, the proportion of recycled PD-L1 was calculated from the 'quenchable' AF488 fluorescence intensity at each time point (MFI of non-requenched sample -MFI of requenched sample) divided by the fluorescence intensity of PD-L1 internalised during the endocytosis step. Immunofluorescence. MDA-MB-231 cells were cultured on coverslips overnight, with or without IFNγ and with or without 50 nM concanamycin A. For mixed cultures, one cell line was labelled with CFSE as per manufacturer's instructions and cultured with unlabelled cells at a 1:1 ratio. Cells were fixed with 4% PFA for 10 min, permeablized with 0.25% Tween-20 in PBS for 10 min, then blocked with 5% BSA, 0.3M glycine in PBST for 1 h. The cells were incubated with the primary antibody at 4 °C overnight. After washing 3 times with PBST, the cells were incubated with the fluorescent conjugated secondary antibody for 1 h at room temperature. The slides were mounted with Prolong Gold and imaged on a Nikon C2 confocal microscope.
Generation and culture of NY-ESO-1-specific CD8
+ T lymphocyte clones. CD8 + T-lymphocyte clones specific for the NY-ESO-1 HLA-Cw3-restricted peptide NY-ESO-1 92-100 and the HLA-A2-restricted peptide NY-ESO-1 157-165 were generated from patients who consented to participate in a clinical research protocol approved by Austin Health Human Research Ethics Committee (HREC H2006/02633). All ethical regulations were complied with. PBMCs were stimulated with 1 × 10 −6 M peptide (Mimotopes), and cultured for 10 days in the presence of 25 IU ml −1 IL-2 (Peprotech). Specific cells were labelled with a fluorescent tetramer Letter reSeArCH (comprising the relevant peptide and HLA (TC Metrix)) and single-cell sorted using a MoFlow cytometer. Clones were expanded with pooled, autologous healthy donor PBMCs as feeder cells, 1 μ g ml −1 phytohaemagglutinin-l (PHA-l (Sigma)) and 600 IU ml −1 IL-2 (Cetus). After approximately 20 days, 1-10 × 10 3 clones were restimulated in the presence of autologous PBMCs as feeder cells, PHA-l and IL-2, as described above. Clone specificity was confirmed by tetramer staining. T lymphocyte clones/lines were cultured in RPMI-1640 media supplemented with 2 mM glutamax, 100 IU ml −1 penicillin, 100 μ g ml −1 streptomycin, 20 mM HEPES, 1% non-essential amino acids, 1 mM sodium pyruvate, 55 μ M β -mercaptoethanol, and 10% human serum (TCRPMI). IL-2 (100 IU ml −1 ) was added and replaced every 3 days. Intracellular cytokine staining of antigen-activated T lymphocytes. NY-ESO-1 antigen-specific T lymphocyte clones were incubated with melanoma cells for 16 to 24 h before addition of 10 μ g ml −1 brefeldin A to the culture medium for a further 6 h. To stain surface markers, cells were washed and labelled with live/dead fixable violet stain (Invitrogen) and antibodies targeting CD3 (BV510), CD8 (FITC) and PD-1 (APC) in PBS for 15 min in the dark at 4 °C, washed and then fixed and permeabilized with BD Cytofix/Cytoperm reagent (BD Biosciences) for 20 min at 4 °C. Cells were stained with anti-TNFα (PE-Cy7) and anti-perforin (PerCp/Cy5.5) in permeabilization solution (BD Biosciences) for 25 min and washed before flow cytometry analysis. Data were acquired on a FACSVerse Flow Cytometer using FACSDiva software and analysed using FlowJo. Cytokine secretion. 20,000 IFNγ pre-treated melanoma cells per well were plated in 96-well plates and 10,000 NY-ESO-1 antigen-specific CTLs were added. Both melanoma cells and T lymphocytes were washed before plating to remove potential contaminating traces of IFNγ or IL-2 from the media. Cells were co-cultured for 72 h and 10 μ g ml −1 of anti-PD-1 antibody was included in the co-culture where indicated. 100 μ l of 200 μ l total supernatant was removed, transferred to a fresh 96-well plate, frozen and sent to http://www.elisakit.com for analysis. Cytokines and chemokines were quantified by multiplex bead array using a 'Cytokine 25-plex Human Panel' on a Luminex platform. Assays were performed in duplicate for untreated control cells and in triplicate for all other samples. To evaluate PD-L1 dependent effects of CMTM6, detected cytokines/chemokines were filtered for those present at altered levels (defined as a change of more than 10%) following inclusion of anti-PD-1 in the co-culture (shown in Fig. 4g, Extended Data Fig. 10g ). The cytokine concentration in co-cultures with CMTM6-depleted cells was compared to control cell cultures and P values calculated in Prism using unpaired two-tailed t-tests with Holm-Sidak correction for multiple testing. Analysis of tumour killing by NY-ESO-1 antigen-specific T lymphocytes. Five or ten thousand melanoma cells per well were plated in a flat-bottom 96-well plate. T lymphocytes were added to selected wells to give the effector to target (E:T) ratios indicated in the figure legends. Samples were incubated at 37 °C for either 24 h (Extended Data Fig. 10c ) or 48 h (Extended Data Fig. 10d, e) . T lymphocytes were resuspended by gentle pipetting and then removed. The plate was washed once with PBS. MTS reagent (CellTiter 96 AQueous One Solution Cell, Promega) was added and samples incubated for 1-2 h at 37 °C. Absorbance at 490 nm was measured and normalized to melanoma samples incubated in absence of T lymphocytes for each cell line to give the percentage of viable cells. Jurkat co-culture IL-2 assays. WM-852 PD-L1-and CMTM6-knockout clones and parental Cas9-expressing WM-852 cells transduced with a control vector (pKLV-U6gRNA-PGKpuro2ABFP) were treated with IFNγ for 24 h. Subsequently, 1 × 10 4 WM-852 cells were plated into 96-well plates in 100 μ l of media and allowed to adhere for 24 h. Jurkat cells were activated with 25 ng ml −1 of PMA and 1 μ g ml Mice were used between 6 and 12 weeks of age and the number of mice per group was selected to provide sufficient statistical power to the experiment according to the expected biological variation. In the experiment shown in Extended Data Fig. 10 , mice were matched according to initial tumour size and randomized to treatment with anti-CTLA-4 9H10 (150 μ g per mouse) or isotype control antibody at days 4, 8 and 12 following tumour cell inoculation. Investigators were not blinded as to group allocation. All animal studies were approved in advance by the Peter MacCallum Animal Ethics and Experimentation Committee and all ethical obligations were complied with. sgRNA target sequences. The following target sequences were used: PD-L1 (g1), 5′-GTTCCCAAGGACCTATATG-3′ ; PD-L1 (g2), 5′-GAACATGAACT GACATGTC-3′ ; CMTM6 (g1), 5′-CAATACACAATCAGTATA-3′ ; CMTM6 (g2), 5′-GCCCGGGTCCTCCTCCGTAG-3′ ; CMTM6 (g3), 5′-GGTGTACAG CCCCACTACGG-3′ ; JAK2 (g1), 5′-GAGCGAACAGTTTCCATC-3′ ; JAK2 (g2), 5′-AACCTGGAAGTGGTCCTTC-3′ . shRNA target sequences. Human CMTM6 (sh1), 5′ -AGGTCAAGAA GGCAGTTTT-3′ ; human CMTM6 (sh2) 5′ -CCCAAGACAGTGAAAGTAA-3′ ; mouse Cmtm6, 5′ -TGCCTAACAGAAAGCGTGT-3′ ; non-targeting, 5′ -GGGTA TCGACGATTACAAA-3′ . qRT-PCR primers. CMTM6, forward 5′-ATGAAGGCCAGCAGAGACAG-3′ , reverse 5′-GTGTACAGCCCCACTACGGA-3′; PD-L1, 5′-GGTGCCGACTAC AAGCGAAT-3′ , reverse 5′-AGCCCTCAGCCTGACATGTC-3′ ; GAPDH, forward 5′-ACAACTTTGGTATCGTGGAAGG-3′ , reverse 5′-GCCATCACGCCACA GTTTC-3′ . 
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Extended Data Figure 6 | CMTM6 shows functional specificity for  PD-L1. a, b, CMTM6 specifically regulates PD-L1, with no effect on cell surface PD-L2 levels in THP-1 cells. THP-1 cells expressing Cas9 and transduced with CMTM6 sgRNA were treated with IFNγ 500 IU ml −1 and TNFα 20 ng ml −1 for 24 h as indicated before staining of cell surface PD-L1 and PD-L2 and analysis by flow cytometry. c, Mass spectrometry analysis identifies PD-L1 as a principal interaction partner of CMTM6. CMTM6 was immunoprecipitated from digitonin lysates of IFNγ -treated MDA-MB-231 cells, and CMTM6-knockout cells as a control. Immunoprecipitates were analysed by mass spectrometry. Table represents all CMTM6 interaction partners identified by at least three unique peptides and absent from the control immunoprecipitation from CMTM6-knockout cells. d, Increased degradation of EndoHresistant PD-L1 species in the absence of CMTM6. IFNγ -treated CMTM6-knockout or parental Cas9-expressing WM-852 cells were pulse-labelled with 35 S-methionine/cysteine for 30 min before chase incubation at 37 °C. PD-L1 was immunoprecipitated from detergent lysates at the indicated times. e, f, IFNγ 500 IU ml −1 was added to CMTM6-knockout and parental Cas9-expressing WM-852 cells and samples taken at the indicated time-points for analysis by flow cytometry. A representative example of an experiment done in biological triplicate is shown. g, Lysates of CMTM6-knockout cells incubated with IFNγ for the indicated times were treated with or without EndoH before SDS-PAGE analysis and immunoblot to assess modification of N-linked glycans on PD-L1 as a marker of passage through the Golgi. 
Extended Data Figure 8 | PD-L1 endocytosis and recycling assays.  a, Internalization assay (relates to data presented in Fig. 3g ). Cells were labelled with unconjugated PD-L1-specific antibodies at 4 °C. After washing off unbound antibody, cells were incubated at 37 °C to allow PD-L1 internalization. Remaining cell surface antibody-labelled PD-L1 was detected with an AF647-conjugated anti-mouse secondary antibody and analysed by flow cytometry. b, Recycling assay 1. Cell surface PD-L1 in IFNγ -treated CMTM6-knockout and Cas9 control WM-852 cells was labelled with an unconjugated PD-L1-specific antibody and allowed to internalize for 30 min at 37 °C as described in a. Remaining cell-surface bound antibody was stripped by washing in pH 2.5 buffer and cells were either kept on ice (post-strip baseline) or re-incubated at 37 °C for the indicated times. Recycled PD-L1 was detected with an AF647-conjugated anti-mouse secondary antibody. c, Recycling assay 2 (relates to data presented in Fig. 3h ). Cells were labelled with an AF488-conjugated PD-L1-specific antibody, washed and incubated at 37 °C to allow endocytosis. Remaining cell surface AF488 was quenched by incubation with an AF488-specific antibody for 1 h on ice before reincubation at 37 °C to allow recycling of antibody-labelled PD-L1. Samples were split and incubated with or without an AF488-specific antibody for 1 h on ice to re-quench cell surface AF488. Recycled PD-L1 was detected by the reappearance of cell surface 'quenchable' AF488 signal. After normalization for incomplete quenching at baseline by subtracting the 'quenchable' AF488 fluorescence at time zero, the fluorescence intensity of recycled PD-L1 at each time-point was compared to that of the total internalised PD-L1 after the endocytosis step to calculate the proportion of PD-L1 recycled. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. The number of mice assigned to each treatment arm was selected to provide sufficient statistical power to discern significant differences in tumour control and overall survival. This was based on prior experience with the model.
Data exclusions
Describe any data exclusions. The only data points excluded were those that were clear outliers due to technical problems in assays done in triplicate experiments.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced. There was some variability in the responses following transplant of CMTM6 or control shRNA-expressing tumours into syngeneic mice. This is highlighted in the text and the results of all experiments performed are presented.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were matched according to initial tumour size and randomised to treatment with anti-CTLA-4 9H10 (150ug/mouse) or isotype control antibody
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding of experiments was not feasible in the assays performed within this project
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
